Serine Hydroxymethyltransferase (SHMT) in biology and disease: molecular mechanisms and therapeutic targeting
Journal of Translational Medicine · 21.04.2026 · 24 (1)
DOI: 10.1186/s12967-026-08044-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Translational Medicine, online erschienen am 21.04.2026. Verfasst von Jia-Ying Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Department of Pharmacology and Laboratory of Aging and Nervous Di…. Hauptthemen laut MEDLINE: Glycine Hydroxymethyltransferase, Molecular Targeted Therapy, Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Serine Hydroxymethyltransferase 1 and 2 (SHMT1/2), as key enzymes in folate metabolism, regulate diverse physiological processes through one-carbon metabolism, including nucleotide biosynthesis, methylation reactions, and redox homeostasis. As a form of metabolic reprogramming, dysregulated SHMT-mediated one-carbon metabolism has been increasingly reported in various human cancers and liver metabolic diseases. Therefore, a concise review of its regulatory roles and disease-associated functions is necessary to clarify its biological and translational significance. Main body This review summarizes the molecular functions of SHMT1/2, with particular emphasis on their central roles in the folate-methionine cycle and serine-glycine metabolic pathway. Beyond their canonical enzymatic activities, SHMT1/2 also exhibit critical non-enzymatic functions. Their activity is tightly regulated by transcription factors and post-translational modifications. SHMT1/2 play significant roles in multiple pathological conditions and are implicated in the initiation and progression of various cancers, such as ovarian, lung, liver, gastric, colorectal, and renal carcinomas. Moreover, SHMT-mediated one-carbon metabolism critically influences liver diseases (e.g., non-alcoholic fatty liver disease, steatohepatitis), inflammatory disorders (e.g., skin inflammation, osteoarthritis), and neurological diseases (e.g., schizophrenia, hypomyelinating leukodystrophy, stroke). Finally, this review discusses the clinical translational potential of SHMT inhibitors in cancer-targeted therapies, offering a theoretical basis for expanding the therapeutic applications of SHMT1/2 in diseases associated with dysregulated one-carbon metabolism.
Conclusions
SHMT1/2 regulate diseases associated with dysregulated one-carbon metabolism through both their enzymatic and non-enzymatic functions. Particularly in cancer, they function as either oncogenes or tumor suppressors in a context-dependent manner, holding significant potential as diagnostic, prognostic, and therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Jiangsu Key Laboratory of Drug Discovery and Translational Res…
ORCID-Profile: Rui Sheng
Förderung
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Li, J. Y., Zhang, X. Q., & Sheng, R. (2026). Serine Hydroxymethyltransferase (SHMT) in biology and disease: molecular mechanisms and therapeutic targeting. Journal of Translational Medicine, 24(1). https://doi.org/10.1186/s12967-026-08044-x
Vancouver
Li JY, Zhang XQ, Sheng R. Serine Hydroxymethyltransferase (SHMT) in biology and disease: molecular mechanisms and therapeutic targeting. Journal of Translational Medicine. 2026;24(1). doi:10.1186/s12967-026-08044-x
BibTeX
@article{Li2026,
author = {Li, Jia-Ying and Zhang, Xue-Qing and Sheng, Rui},
title = {Serine Hydroxymethyltransferase (SHMT) in biology and disease: molecular mechanisms and therapeutic targeting},
journal = {Journal of Translational Medicine},
year = {2026},
volume = {24},
number = {1},
doi = {10.1186/s12967-026-08044-x}
}
EUVIMED